{"document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS"}, "news_desk": "Business", "slideshow_credits": null, "abstract": "European regulators announce start of safety review of Gilead Sciences\u2019 leukemia drug Zydelig following rise in number of harmful events reports, including deaths, during three clinical trials.", "multimedia": [], "headline": {"content_kicker": "Business Briefing", "print_headline": "Europe Investigates Safety of Gilead Leukemia Drug", "main": "Europe Investigates Safety of Gilead Leukemia Drug"}, "print_page": "2", "keywords": [{"value": "Gilead Sciences Inc", "is_major": "Y", "rank": "1", "name": "organizations"}, {"value": "Leukemia", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Europe", "is_major": "Y", "rank": "3", "name": "glocations"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "4", "name": "subject"}, {"value": "European Medicines Agency", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Roche Holding AG", "is_major": "N", "rank": "6", "name": "organizations"}], "snippet": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "source": "The New York Times", "lead_paragraph": "European regulators have started a review into the safety of Gilead Sciences\u2019 leukemia drug Zydelig over concerns about serious adverse events, including deaths.", "word_count": "84", "pub_date": "2016-03-12T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/03/12/business/europe-investigates-safety-of-gilead-leukemia-drug.html", "_id": "56e360f638f0d81b768a68a3"}